Mazindol CR is under clinical development by NLS Pharmaceutics and currently in Phase II for Opium (Opioid) Addiction. According to GlobalData, Phase II drugs for Opium (Opioid) Addiction have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mazindol CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mazindol CR overview
Mazindol is under development for the treatment of attention deficit hyperactivity disorder and opioid use disorder. It is a controlled release formulation administered through the oral route. It targets dopamine and norepinephrine reuptake.
It was also under development for sleep disorders and cognitive impairment.
NLS Pharmaceutics overview
NLS Pharmaceutics (NLS Pharma) is a drug development company that focuses on a strong scientific understanding of neurobehavioral and neurocognitive disorders and their pharmacognosy. NLS Pharma is headquartered in Stans, Switzerland.
For a complete picture of Mazindol CR’s drug-specific PTSR and LoA scores, buy the report here.